Therefore, the down-regulation of FABP1 could enhance lipotoxicity of free fatty acids, contributing to inflammation, steatohepatitis and non-alcoholic fatty liver disease (NAFLD) progression (Neuschwander-Tetri, 2010; Guzmán et al., 2013). Here, FABP1 is linked to metabolic dysfunction-associated steatotic liver disease.